ClinicalTrials.gg
TerminatedNCT03994705Updated May 15, 2025Results posted

Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

A Phase 1 interventional study of Descartes-11 and Fludarabine in Multiple Myeloma, sponsored by Cartesian Therapeutics. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Cartesian Therapeutics · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Phase 1 enrollment completed. Further clinical development terminated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 2,168 studies in Multiple Myeloma with a site in United States — 273 open to participants now, 501 under way, 66 of them phase 3. Multiple Myeloma · United States.

Enrollment
1,308th of 1,901
20 · median 36
Started
2019
with 84 others
Phase 1
559 of 2,168
64 open now
Registered
1,544th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,308th largest by enrollment of the 1,901 interventional ones that give a count, is one of 85 that started in 2019, is one of 559 in phase 1, and was the 1,544th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

273 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

268 more — sign in →

All 273 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • CAR-T
  • CART
  • CAR T Cell
  • CAR T-Cell
  • Multiple Myeloma
  • BCMA
  • B cell maturation antigen
  • B-cell maturation antigen
  • Descartes-11
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Active multiple myeloma that is after at least 2 ;
  • ;
  • adequate vital organ function; and
  • no active infection.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Dose Level 1

    Participants were administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 10 million cells of Descartes-11 via intravenous catheter on Days 7,14

    Biological: Descartes-11 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Dose Level 2

    Participants were administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 32 million cells of Descartes-11 via intravenous catheter on Days 7,14

    Biological: Descartes-11 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Dose Level 3

    Participants were administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 100 million cells of Descartes-11 via intravenous catheter on Days 7,14

    Biological: Descartes-11 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Dose Level 4 A

    Participants were administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 150 million cells of Descartes-11 via intravenous catheter on Days 7,14,21

    Biological: Descartes-11 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Dose Level 4B

    Participants were administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 150 million cells of Descartes-11 via intravenous catheter on Days 7,10,14,21

    Biological: Descartes-11 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Dose Level 4C

    Participants were not administered Cyclophosphamide and Fludarabine for preconditioning on Days 1,2,3 Participants were administered 150 million cells of Descartes-11 via intravenous catheter on Days 1,4, 7,10,14,21

    Biological: Descartes-11

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Related Adverse Events

    Determine the safety of Descartes-11 in patients with relapsed/refractory multiple myeloma

    Time frame: Time Frame: 21 days

Secondary outcomes

  1. Disease Assessment Based on International Myeloma Working Group (IMWG) Criteria

    Patience with Complete response (CR) according to the International Myeloma Working Group (IMWG).

    Time frame: Disease assessment is on Day 21 (or at least 14 days after first Descartes-11 infusion)

07

Results

Posted Apr 25, 2025

Participant flow

Participant flow — Overall Study
MilestoneDecartes-11 Dose Level 1Descates-11 Level 2Descartes-11 Dose Level 3Descartes-11 Dose Level 4ADescartes-11 Dose Level 4BDescartes-11 Dose Level 4C
Started343244
Completed343244
Not completed000000

Outcome measures

PrimaryNumber of Participants With Treatment-Related Adverse Events

Determine the safety of Descartes-11 in patients with relapsed/refractory multiple myeloma

Time frame:
Time Frame: 21 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Adverse Events
ParticipantsDose-Escalation Level 1Dose Level 2Dose Level 3Dose Level 4ADose Level 4BDose Level 4C
Number of Participants With Treatment-Related Adverse Events011000
SecondaryDisease Assessment Based on International Myeloma Working Group (IMWG) Criteria

Patience with Complete response (CR) according to the International Myeloma Working Group (IMWG).

Time frame:
Disease assessment is on Day 21 (or at least 14 days after first Descartes-11 infusion)
Reported as:
Count of participants · Participants
Disease Assessment Based on International Myeloma Working Group (IMWG) Criteria
ParticipantsDose-Escalation Level 1Dose Level 2Dose Level 3Dose Level 4ADose Level 4BDose Level 4C
Disease Assessment Based on International Myeloma Working Group (IMWG) Criteria000000

Adverse events

Collected over Follow ups conducted on months 3,6,9,12.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 10/3 (0%)3/3 (100%)3/3 (100%)
Dose Level 21/4 (25%)2/4 (50%)2/4 (50%)
Dose Level 30/3 (0%)1/3 (33.3%)2/3 (66.7%)
Dose Level 4A0/2 (0%)1/2 (50%)1/2 (50%)
Dose Level 4B0/4 (0%)1/4 (25%)3/4 (75%)
Dose Level 4C1/4 (25%)0/4 (0%)2/4 (50%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventDose Level 1Dose Level 2Dose Level 3Dose Level 4ADose Level 4BDose Level 4C
Generalized weaknessMusculoskeletal and connective tissue disorders2/30/40/30/20/40/4
HypotensionBlood and lymphatic system disorders2/30/40/30/20/40/4
Neck PainMusculoskeletal and connective tissue disorders0/30/40/31/20/40/4
Febrile NeutropeniaImmune system disorders1/31/41/30/20/40/4
PlasmacytomaBlood and lymphatic system disorders0/30/41/30/20/40/4
Dental InfectionInfections and infestations0/30/41/30/20/40/4
HypoxiaBlood and lymphatic system disorders1/30/40/30/20/40/4
Fever, etiology unknownImmune system disorders1/30/40/30/20/40/4
Upper Resipratory InfectionRespiratory, thoracic and mediastinal disorders1/30/40/30/20/40/4
IleusGastrointestinal disorders0/31/40/30/20/40/4
Most frequent other events
Showing 10 of 19
Most frequent other events
EventDose Level 1Dose Level 2Dose Level 3Dose Level 4ADose Level 4BDose Level 4C
AnemiaBlood and lymphatic system disorders3/32/41/31/22/41/4
Aspartate aminotransferase increasedGastrointestinal disorders2/30/40/30/21/40/4
Back painMusculoskeletal and connective tissue disorders2/31/41/30/20/41/4
Infusion Related ReactionImmune system disorders0/32/42/30/20/40/4
FatigueGeneral disorders1/32/40/30/20/40/4
HypoalbuminemiaMetabolism and nutrition disorders1/32/41/30/20/40/4
ConstipationGastrointestinal disorders1/30/40/31/20/40/4
DysphagiaGastrointestinal disorders1/30/40/31/20/40/4
HyperglycemiaMetabolism and nutrition disorders1/30/40/31/21/41/4
Chronic Kidney DiseaseRenal and urinary disorders1/30/40/30/20/40/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Level 1 DoseLevel 2 DoseLevel 3 DoseLevel 4ALevel 4BLevel 4CTotal
<=18 years0000000
Between 18 and 65 years2320018
>=65 years11124312
Sex: Female, Male
Sex: Female, Male(Participants)Level 1 DoseLevel 2 DoseLevel 3 DoseLevel 4ALevel 4BLevel 4CTotal
Female1211207
Male22212413
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Level 1 DoseLevel 2 DoseLevel 3 DoseLevel 4ALevel 4BLevel 4CTotal
White33324216
Asian0100001
Other-Non Hispanic0000011
White (Hispanic)0000022
Region of Enrollment
Region of Enrollment(participants)Level 1 DoseLevel 2 DoseLevel 3 DoseLevel 4ALevel 4BLevel 4CTotal
United States34324420
08

Study locations

2 sites
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Medical College of Wisconsin
    Madison, Wisconsin 53226, United States
09

References and documents

Publications

  • Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013 Jul;1(1):26-31. doi: 10.1158/2326-6066.CIR-13-0006. Epub 2013 Apr 7. PubMed 24777247 ↗
  • Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170. PubMed 24579088 ↗
  • Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13. PubMed 27076371 ↗
  • Lim WA, June CH. The Principles of Engineering Immune Cells to Treat Cancer. Cell. 2017 Feb 9;168(4):724-740. doi: 10.1016/j.cell.2017.01.016. PubMed 28187291 ↗
  • Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20. PubMed 27207799 ↗
  • Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13. PubMed 27412889 ↗
  • GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18. PubMed 25530442 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in May 2021, 21 months.

Results were first posted in Apr 2025, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2019
First posted
Jun 21, 2019
StartActual
Aug 1, 2019
Primary completionActual
May 27, 2021
CompletionActual
Jun 11, 2021
Results first posted
Apr 25, 2025
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03994705
Lead sponsor
Cartesian Therapeutics
Responsible party
Sponsor
First posted
Jun 21, 2019
Start date
Aug 1, 2019
Primary completion
May 27, 2021
Completion
Jun 11, 2021
Results posted
Apr 25, 2025
Last update
May 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion